格隆汇10月14日丨创业慧康(300451.SZ)公布，近日收到飞利浦（中国）投资有限公司（简称"飞利浦"） 出具的《告知函》，飞利浦已通过集中竞价及大宗交易方式合计减持公司股份15,793,764股，占公司总 股本1.019528%（占剔除公司回购专用账户股份后的总股本比例为1.022630%）。 ...

每经AI快讯，10月14日，创业慧康（300451）(300451.SZ)公告称，公司收到飞利浦(中国)投资有限公司 出具的《告知函》，飞利浦于2025年9月25日至2025年10月10日通过集中竞价及大宗交易方式合计减持 公司股份约1579万股，占公司总股本1.019528%，所持公司股份比例从9.999996%下降至8.977366%。本 次权益变动不会导致公司控制权发生变更，不会对公司治理结构及持续经营产生重大影响。 ...

Core Viewpoint - The company, Chuangye Huikang (300451.SZ), announced that Philips (China) Investment Co., Ltd. will reduce its shareholding in the company from 9.999996% to 8.977366% through centralized bidding and block trading, totaling 15.79 million shares, which will not affect the company's control or governance structure [1] Summary by Relevant Sections - **Shareholding Change** - Philips will reduce its stake in Chuangye Huikang by 15.79 million shares, decreasing its ownership percentage from 9.999996% to 8.977366% [1] - The total shares reduced represent approximately 1.019528% of the company's total share capital [1] - **Impact on Company** - The reduction in shareholding will not lead to a change in control of the company [1] - There will be no significant impact on the company's governance structure or ongoing operations [1]

证券代码：300451 证券简称：创业慧康 公告编号：2025-056 创业慧康科技股份有限公司 | 1.基本情况 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 信息披露义务人 | | | 飞利浦（中国）投资有限公司 | | | | | 住所 | | 上海市静安区灵石路718号A1幢 | | | | | | 权益变动时间 | | 2025年10月10日 飞利浦（中国）投资有限公司基于自身战略安排和需求， | | | | | | 权益变动过程 | | 于2025年9月25日至2025年10月10日通过集中竞价及大宗交易 方式合计减持公司股份15,793,764股，所持公司股份比例从 9.999996%下降至8.977366%（注：总股本按剔除公司回购专 用账户中的股份数量4,698,200股后的股数1,544,426,492股计 算，下同），权益变动触及1%的整数倍。 本次权益变动不会导致公司控制权发生变更，不会对公司 | | | | | | 股票简称 | | 治理结构及持续经营产生重大影响。 创业慧康 300451 | 股票代码 | | ...

Core Viewpoint - The company, Chuangshihui Kang (300451.SZ), focuses on the field of healthcare information technology, emphasizing smart healthcare, regional health, and healthy cities as its core development directions [1] Company Focus - The company is currently not involved in smart government services [1]

Core Viewpoint - The company, Chuangshihui Kang (300451.SZ), remains focused on the field of healthcare information technology, emphasizing smart healthcare, regional health, and healthy cities as its core development directions [1] Company Focus - The company does not currently engage in smart government business [1]

Core Viewpoint - The company is focused on deepening its presence in the domestic healthcare information market, prioritizing service quality and meeting domestic demand, while not expanding its business in the U.S. at this stage [1] Group 1 - The company is committed to enhancing service quality in the domestic healthcare information sector [1] - The primary task for the company is to meet domestic demand [1] - Currently, the company has not expanded its business operations in the United States [1]

Group 1 - The core transaction involved 1.95 million shares of Chuangye Huikang, with a total transaction value of 7.761 million yuan, accounting for 5.58% of the total trading volume on that day [1] - The transaction price was 3.98 yuan per share, representing a discount of 14.96% compared to the market closing price of 4.68 yuan [1][2] - The buyer was an institutional investor, specifically the Institutional Special Account, while the seller was China International Capital Corporation Limited, Shanghai Branch [2]

Group 1 - The core point of the article is that a major shareholder of Chuangyue Huikang, Ge Hang, plans to reduce his holdings by up to 37.038 million shares [1][2] - The reduction will occur within a three-month period starting from October 23, 2025, to January 22, 2026 [1][2] - The planned reduction includes a maximum of 6.1495 million shares through centralized bidding, accounting for 0.3982% of the total shares excluding repurchased shares [1][2] - Additionally, Ge Hang intends to reduce up to 30.8885 million shares through block trading, representing 2.0000% of the total shares excluding repurchased shares [1][2] - In total, the reduction will not exceed 37.038 million shares, which is 2.3982% of the total share capital after excluding repurchased shares [1][2]

Company Overview - Chuangshi Huikang (SZ 300451) held its 19th meeting of the 8th Board of Directors on September 29, 2025, discussing the revision of the "Board Secretary Work Guidelines" [1] - As of the report date, Chuangshi Huikang has a market capitalization of 7.4 billion yuan [1] Financial Performance - For the first half of 2025, Chuangshi Huikang's revenue composition was 94.1% from the medical industry and 5.9% from other businesses [1]